Evidence map›Paper›PMID 40789865›Full record

ArticleNPJ vaccines2025

Systems biology-based assessment of immune responses to whole cell and acellular pertussis vaccines.

Mariana Leguia, Antón Vila-Sanjurjo, Diana Juarez, Alejandra Garcia-Glaessner, Ana I Gil, Mayita Alvarez, Rubelio Cornejo, Sami Cherikh, Casey E Gelber, Johannes B Goll and 5 more

Abstract read
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mariana LeguiaGenomics Laboratory, Pontificia Universidad Católica del Perú (PUCP), Lima, Peru. mariana.leguia@pucp.edu.pe.
Antón Vila-SanjurjoCICA - Centro Interdisciplinar de Química e Bioloxía, Departamento de Bioloxía, Facultade de Ciencias, Universidade da Coruña, Campus de Elviña, Coruña, Spain.
Diana JuarezGenomics Laboratory, Pontificia Universidad Católica del Perú (PUCP), Lima, Peru.
Alejandra Garcia-GlaessnerGenomics Laboratory, Pontificia Universidad Católica del Perú (PUCP), Lima, Peru.
Ana I GilInstituto de Investigación Nutricional, Lima, Peru.
Mayita AlvarezInstituto de Investigación Nutricional, Lima, Peru.
Rubelio CornejoInstituto de Investigación Nutricional, Lima, Peru.
Sami CherikhThe Emmes Company, Rockville, MD, USA.
Casey E GelberThe Emmes Company, Rockville, MD, USA.
Johannes B GollThe Emmes Company, Rockville, MD, USA.
Leigh M HowardVanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Natalia Jimenez-TruqueVanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Kathryn M EdwardsVanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
C Buddy CreechVanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Claudio F LanataInstituto de Investigación Nutricional, Lima, Peru.

Funding

NIH-NIAID HSN2722001300023I, Task Order 17
6 · The paper itself

Abstract

Given the local and systemic adverse reactions associated with whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids (DTP), acellular pertussis vaccines combined with the same toxoids (DTaP) were developed in the 1990s. In comparison to DTP, DTaP vaccines demonstrated reduced reactogenicity and equivalent or improved immunogenicity and efficacy. However, there has been a resurgence of pertussis disease, particularly in DTaP-vaccinated children, suggesting that immunity wanes more quickly with DTaP vaccination. To elucidate the differences in immune responses to DTP and DTaP vaccines, we employed a systems biology-based strategy to compare global changes in gene expression following primary vaccination with either DTP or DTaP. We used RNA-Seq and ribosome profiling (RP) to identify transcriptional and translational signatures, respectively, in peripheral blood mononuclear cells (PBMCs) collected from 50 infant recipients of DTP or DTaP at two time-points (baseline (pre-vaccination at Day 1) and either Day 2 or 8 post-vaccination). We also used standard serologic methods to assess immunogenicity, and correlated these results with transcriptional and translational signatures. Here, we provide a detailed description of the rationale, experimental design, methodology, and enrollment procedures used. Given the technical complexity of our approach, our objective is to fill knowledge gaps, describe key quality metrics, and support future publications. In brief, we recovered 4-12 million PBMCs (average 8.9 million) with 99% viability per 2.5 mL blood sample, enabling excellent nucleic acid recovery yields for the preparation of high-quality sequencing libraries. In turn, these generated RNA-Seq and RP datasets with sufficient genome coverage breadth and depth to enable differential gene expression analyses, demonstrating the validity of this approach to study pertussis vaccine immunology specifically, and its utility to characterize mechanisms of the human immune response to vaccination generally.

Identifiers

PMID40789865
PMCPMC12340147

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.